From the Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada.
Department of Pain Medicine, Singapore General Hospital, Singapore.
Anesth Analg. 2019 Sep;129(3):874-881. doi: 10.1213/ANE.0000000000003963.
The recreational and medical use of cannabinoids has been increasing. While most studies and reviews have focused on the role of cannabinoids in the management of acute pain, no study has examined the postoperative outcomes of surgical candidates who are on cannabinoids preoperatively. This retrospective cohort study examined the impact of preoperative cannabinoid use on postoperative pain scores and pain-related outcomes in patients undergoing major orthopedic surgery.
Outcomes of patients who had major orthopedic surgery at our hospital between April 1, 2015 and June 30, 2017 were reviewed. Data were obtained from Networked Online Processing of Acute Pain Information, a locally developed database for our Acute Pain Service. Propensity score matching was used to balance baselines variables including age, sex, type of surgery, history of depression or anxiety, and perioperative use of regional anesthesia between patients who reported use of cannabinoids and those not on this substance. Intensity of pain with movement in the early postoperative period (defined as up to 36 hours after surgery) was the primary outcome of this study. The secondary outcomes (all in early postoperative period) were pain at rest, opioid consumption, incidence of pruritus, nausea and vomiting, sedation, delirium, constipation, impairment of sleep and physical activity, patient satisfaction with analgesia, and the length of Acute Pain Service follow-up.
A total of 3793 patients were included in the study. Of these, 155 patients were identified as being on cannabinoids for recreational or medical indications in the preoperative period. After propensity score matching, we compared data from 155 patients who were on cannabinoids and 155 patients who were not on cannabinoids. Patients who were on preoperative cannabinoids had higher pain numerical rating score (median [25th, 75th percentiles]) at rest (5.0 [3.0, 6.1] vs 3.0 [2.0, 5.5], P = .010) and with movement (8.0 [6.0, 9.0] vs 7.0 [3.5, 8.5], P = .003), and a higher incidence of moderate-to-severe pain at rest (62.3% vs 45.5%, respectively, P = .004; odds ratio, 1.98; 95% CI, 1.25-3.14) and with movement (85.7% vs 75.2% respectively, P = .021; odds ratio, 1.98; 95% CI, 1.10-3.57) in the early postoperative period compared to patients who were not on cannabinoids. There was also a higher incidence of sleep interruption in the early postoperative period for patients who used cannabinoids.
This retrospective study with propensity-matched cohorts showed that cannabinoid use was associated with higher pain scores and a poorer quality of sleep in the early postoperative period in patients undergoing major orthopedic surgery.
大麻素的娱乐和医疗用途一直在增加。虽然大多数研究和综述都集中在大麻素在管理急性疼痛方面的作用,但没有研究检查术前使用大麻素的手术患者的术后结果。这项回顾性队列研究检查了术前使用大麻素对接受大骨科手术患者术后疼痛评分和与疼痛相关结果的影响。
对我院 2015 年 4 月 1 日至 2017 年 6 月 30 日期间接受大骨科手术的患者的治疗结果进行了回顾。数据来自于我们急性疼痛服务部开发的本地网络急性疼痛信息处理系统。使用倾向评分匹配来平衡基线变量,包括年龄、性别、手术类型、抑郁或焦虑史以及围手术期使用区域麻醉,以比较报告使用大麻素和未使用该物质的患者。本研究的主要结局是术后早期(定义为术后 36 小时内)运动时的疼痛强度。次要结局(均在术后早期)包括静息时疼痛、阿片类药物消耗、瘙痒发生率、恶心和呕吐、镇静、谵妄、便秘、睡眠和体力活动受损、患者对镇痛的满意度以及急性疼痛服务随访时间。
共有 3793 名患者纳入本研究。其中,155 名患者术前因娱乐或医疗原因使用大麻素。在进行倾向评分匹配后,我们比较了 155 名术前使用大麻素的患者和 155 名未使用大麻素的患者的数据。术前使用大麻素的患者静息时疼痛数字评分中位数(25%,75%)更高(5.0[3.0,6.1]与 3.0[2.0,5.5],P=0.010),运动时疼痛数字评分中位数(8.0[6.0,9.0]与 7.0[3.5,8.5],P=0.003),静息时中度至重度疼痛发生率更高(分别为 62.3%和 45.5%,P=0.004;优势比,1.98;95%置信区间,1.25-3.14)和运动时(分别为 85.7%和 75.2%,P=0.021;优势比,1.98;95%置信区间,1.10-3.57)与未使用大麻素的患者相比。在术后早期,使用大麻素的患者睡眠中断的发生率也更高。
这项使用倾向评分匹配队列的回顾性研究表明,在接受大骨科手术的患者中,术前使用大麻素与术后早期疼痛评分更高和睡眠质量更差有关。